Entera Bio Receivables

Entera Bio (ENTX) currently reports a receivables of $0 as of March 2026. That compares with $130K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Entera Bio's receivables history and peer comparisons.

Entera Bio's receivables decreased from $130K to $0 — a 100.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entera Bio reported $0 in receivables as of March 2026. That compares with $130K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entera Bio, and consider following ENTX for alerts when major investors trade the stock.

Entera Bio is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTX with unrelated industries.